Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.
Raymond S McDermottJohn GreeneJohn McCaffreyImelda ParkerSylva HelanovaAnne-Marie BairdAusra TeiserskieneMarvin LimHelen MatthewsOlwyn DeignanJohn FeeneyPierre G ThirionStephen P FinnPaul J KellyPublished in: Therapeutic advances in medical oncology (2021)
In men with progressive mCRPC and bone metastases, the combination of radium-223 and enzalutamide was tolerable with the majority of patients completing the combination treatment. Bone fractures during the combination period were uncommon; however, we did identify a higher incidence of fractures occurring in patients after completing combination treatment. Bone health agents should be administered and bone health should be closely monitored following treatment with radium-223 and enzalutamide.
Keyphrases
- prostate cancer
- end stage renal disease
- open label
- phase ii
- healthcare
- newly diagnosed
- ejection fraction
- chronic kidney disease
- squamous cell carcinoma
- bone mineral density
- prognostic factors
- randomized controlled trial
- multiple sclerosis
- risk factors
- radiation therapy
- risk assessment
- climate change
- bone regeneration
- double blind
- locally advanced